精准医学在 2 型糖尿病管理中的应用。
Precision medicine in the management of type 2 diabetes.
机构信息
Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
出版信息
Lancet Diabetes Endocrinol. 2018 Nov;6(11):891-900. doi: 10.1016/S2213-8587(18)30052-4. Epub 2018 Apr 23.
The study of type 2 diabetes has been driven by advances in human genetics, epigenetics, biomarkers, mechanistic studies, and large clinical trials, enabling new insights into disease susceptibility, pathophysiology, progression, and development of complications. Simultaneously, several new drug classes with different mechanisms of action have been introduced over the past two decades, accompanied by data about cardiovascular safety and non-glycaemic outcomes. In this Review, we critically examine the progress and integration of this new science into clinical practice, and review opportunities for enabling the use of precision medicine in the diagnosis and treatment of type 2 diabetes. We contrast the success in delivering personalised medicine for monogenic diabetes with the greater challenge of providing a precision medicine approach for type 2 diabetes, highlighting gaps, limitations, and areas requiring further study.
2 型糖尿病的研究受到人类遗传学、表观遗传学、生物标志物、机制研究和大型临床试验的推动，使人们对疾病易感性、病理生理学、进展和并发症的发展有了新的认识。与此同时，在过去的二十年中，引入了几种具有不同作用机制的新药类别，并提供了关于心血管安全性和非血糖结果的数据。在这篇综述中，我们批判性地检查了这一新科学在临床实践中的进展和整合，并回顾了在 2 型糖尿病的诊断和治疗中应用精准医学的机会。我们对比了单基因糖尿病个体化药物治疗的成功，以及为 2 型糖尿病提供精准医学方法的更大挑战，突出了差距、局限性和需要进一步研究的领域。
Zotero 插件